Cancer Vaccine Missed Primary Endpoint in Clinical Trial
The experimental treatment SurVaxM failed to meet its goal for all participants with glioblastoma.
Updated on Oct. 7, 2026 in Cancer
Live Poll
Should companies continue developing drugs if clinical trials fail to meet their primary efficacy endpoints?
MimiVax announced that its investigational cancer vaccine, SurVaxM, did not meet its primary efficacy endpoint in a phase 2 clinical trial for glioblastoma. The study enrolled 233 evaluable patients to test the vaccine alongside standard-of-care therapies.
Why it matters
No new glioblastoma treatments have been approved in over two decades, making the search for effective therapies a critical priority for patients. This trial result indicates that the vaccine did not demonstrate the intended broad efficacy, though researchers continue to analyze the data for potential patient subgroups.
This phase 2 trial evaluated 233 patients receiving SurVaxM alongside standard-of-care tumor resection, chemotherapy, and radiotherapy. While the trial missed its primary endpoint, preliminary analysis showed a potential survival advantage in patients aged 65 and younger.
The players
MimiVax
A biotechnology company focused on developing immunotherapies for cancer, including the vaccine SurVaxM.
Roswell Park Comprehensive Cancer Center
An oncology research institution based in Buffalo that focuses on advanced cancer treatment and clinical trials.
BrainChild Bio
A clinical-stage biotechnology company specializing in therapies for pediatric brain cancers.
The details
SurVaxM is designed to target survivin, a protein that prevents programmed cell death in tumor cells. Patients in the study received four primary injections over two weeks, followed by booster injections every two months. Adverse events of Grade 3 or higher were reported in 48% of the treatment group and 46% of the placebo group.
Timeline
2005 marked the addition of temozolomide as standard-of-care for glioblastoma.
2012 saw the formation of MimiVax as a spin-out from Roswell Park Comprehensive Cancer Center.
2022 was the year the phase 2a trial of SurVaxM concluded.
October 7, 2026, was the date MimiVax announced these study results.
Next year marks the expected entry into clinics for a pediatric brain cancer therapy from BrainChild Bio.
Health Landscape
Glioblastoma treatment options have remained largely unchanged since the 2005 introduction of temozolomide as the standard-of-care. This trial result highlights the persistent difficulty in clinical development for this aggressive form of brain cancer.
If you are currently managing a glioblastoma diagnosis, it is worth discussing these recent trial findings with your oncologist to understand how they relate to current treatment options. Clinical trials remain a critical pathway for accessing new research, and your physician can provide guidance on appropriate opportunities.
The takeaway
While the SurVaxM vaccine did not meet its primary study goals, researchers observed potential benefits for specific age groups that may influence future development paths. Patients should always consult their oncology team regarding new data and available clinical trial enrollments.
Further reading
For context on the current approaches to managing brain tumors, visit Cancer.
Live Poll
Should companies continue developing drugs if clinical trials fail to meet their primary efficacy endpoints?
